Merck: another priority review granted to Keytruda

(CercleFinance.com) - Merck said that its immunotherapy Keytruda has been granted a priority review status by the US Food and Drug Administration for the treatment of head and neck cancer, which thereby accelerates its regulatory approval.


The FDA has accepted a new supplemental Biologics License Application (sBLA) for the drug for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), the company said in a statement on Monday.

The FDA has set a decision date for 10 June 2019.

Keytruda is already indicated for the treatment of numerous cancers, such as lung cancer and Hodgkin lymphoma.

Copyright (c) 2019 CercleFinance.com. All rights reserved.